Natixis Advisors LLC Increases Position in Alkermes plc (NASDAQ:ALKS)

Natixis Advisors LLC increased its holdings in Alkermes plc (NASDAQ:ALKS - Free Report) by 190.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 36,490 shares of the company's stock after acquiring an additional 23,921 shares during the period. Natixis Advisors LLC's holdings in Alkermes were worth $1,021,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. V Square Quantitative Management LLC purchased a new position in shares of Alkermes during the 3rd quarter worth $29,000. Signaturefd LLC raised its stake in shares of Alkermes by 51.2% in the 2nd quarter. Signaturefd LLC now owns 1,417 shares of the company's stock valued at $34,000 after acquiring an additional 480 shares during the period. Hexagon Capital Partners LLC lifted its holdings in shares of Alkermes by 3,841.0% in the 2nd quarter. Hexagon Capital Partners LLC now owns 1,537 shares of the company's stock worth $37,000 after acquiring an additional 1,498 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Alkermes by 44.4% in the 2nd quarter. GAMMA Investing LLC now owns 2,287 shares of the company's stock worth $55,000 after acquiring an additional 703 shares during the last quarter. Finally, Archer Investment Corp boosted its position in shares of Alkermes by 28.6% during the 3rd quarter. Archer Investment Corp now owns 4,500 shares of the company's stock worth $126,000 after purchasing an additional 1,000 shares during the period. Institutional investors and hedge funds own 95.21% of the company's stock.

Insider Activity

In other news, SVP Christian Todd Nichols sold 5,208 shares of the business's stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total value of $151,813.20. Following the completion of the sale, the senior vice president now directly owns 60,703 shares of the company's stock, valued at approximately $1,769,492.45. The trade was a 7.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Craig C. Hopkinson sold 58,996 shares of Alkermes stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $30.08, for a total value of $1,774,599.68. Following the transaction, the executive vice president now directly owns 83,300 shares in the company, valued at approximately $2,505,664. This trade represents a 41.46 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 74,675 shares of company stock worth $2,235,622. 4.89% of the stock is currently owned by insiders.

Alkermes Stock Up 0.2 %

NASDAQ:ALKS traded up $0.07 during trading hours on Wednesday, hitting $29.32. The company's stock had a trading volume of 943,192 shares, compared to its average volume of 1,825,540. Alkermes plc has a 52-week low of $22.22 and a 52-week high of $32.88. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $4.74 billion, a P/E ratio of 15.04, a price-to-earnings-growth ratio of 0.98 and a beta of 0.47. The stock has a fifty day moving average of $27.98 and a 200-day moving average of $26.47.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. JPMorgan Chase & Co. decreased their price target on Alkermes from $32.00 to $26.00 and set a "neutral" rating on the stock in a research note on Friday, October 25th. Cantor Fitzgerald decreased their target price on Alkermes from $48.00 to $43.00 and set an "overweight" rating on the stock in a research note on Friday, October 25th. HC Wainwright reaffirmed a "neutral" rating and issued a $37.00 target price on shares of Alkermes in a research report on Friday, October 25th. Piper Sandler reissued an "overweight" rating and set a $37.00 price target (down previously from $38.00) on shares of Alkermes in a research report on Friday, October 25th. Finally, Mizuho lifted their price objective on shares of Alkermes from $35.00 to $40.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $35.42.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.